FDA Peptide Reclassification 2026: What It Means for Providers BPC 157 & TB 500 Blend 10mg 10mg Peptide Tech The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York After being placed into FDA Category 2 in 2023, several widely discussed peptides faced restricted pathways for regulated compounding. This shift pushed demand toward unregulated markets and created significant uncertainty across the FDA's new guidelines on bulk drug compounding Pharmacy & Healthcare Legal Blog FDA Peptide Reclassification: What This Means For Weight Loss, Recovery, And More